GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are down after the company released its third-quarter earnings report Tuesday afternoon.

GW Pharmaceuticals Reports Q3 Sales Beat, Stock Falls

GW Pharmaceuticals stock collapsed after the biotech company reported $91 million in sales for its third quarter ended Sept. 30. That beat expectations for $87 million in quarterly sales.

Shares Of This CBD Oil-Selling Biotech Crashed Despite Quarterly Beat

GW Pharmaceuticals (NASDAQ: GWPH) releases its next round of earnings this Tuesday, November 5.

GW Pharmaceuticals Q4 Earnings Outlook

MacroGenics

Insulet

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

3 'Medical Product' Stocks Likely to Beat This Earnings Season

Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.

What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?

Stock price has been hit by factors outside the company's control.

GW Pharma Earnings Present Buying Opportunity

Cannabis-based medicine is already bringing relief to many with more potential ahead.

Is GW Pharmaceuticals an Opportunity Before Earnings?

GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $118.11, moving -0.85% from the previous trading session.

GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

Investors have pummeled GW stock recently, an analyst said, following recent concerns over prescriptions of its CBD oil, Epidiolex. Data suggest prescriptions slowed in early October.

Can This Biotech Stock Overcome Worries Plaguing Its Approved CBD Oil?

Levi Strauss

Levi Strauss and GW Pharmaceuticals really took it on the chin from investors.

Consider Buying These 2 Stocks That Got Crushed on Tuesday

Investors pared back some of the stock's recent gains as optimism faded in the wider marijuana niche.

Why GW Pharmaceuticals Stock Lost 19% in September

Is  (GWPH) Outperforming Other Medical Stocks This Year?

Is GW Pharmaceuticals (GWPH) Stock Outpacing Its Medical Peers This Year?

Canopy Growth

Innovative Industrial Properties

Marijuana stocks have reversed recent losses as report finds that Americans favor decriminalizing all drugs. Thus, investing in cannabis stocks for the moment won't be a bad proposition.

Pot Stocks to Win as America Roots for Decriminalizing Drugs

GW Pharmaceuticals share price dropped, and the stock is selling at a fair price with plenty of room to move back higher.

4 Reasons To Buy GW Pharmaceuticals

Approval in Europe for its cannabidiol-based drug will give the company another lucrative market to tap into.

GW Pharmaceuticals Just Unlocked a Significant Growth Opportunity

Oppenheimer cut its stock price target for GW Pharmaceuticals PLC GWPH, +3.37% on Friday, after a poll of 25 prescribers of the company's Epidiolex, the only cannabis-based drug to win U.S.

Oppenheimer lowers GW Pharma price target, tweaks revenue forecasts for Epidiolex

Cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CEO Justin Gover told CNBC's Jim Cramer the company's approval to market Epidiolex across Europe is a "historic milestone" for the field of cannabinoid science.

'Renewed Sense Of Hope': GW Pharma CEO Talks Epilepsy Drug Approval In Europe

Aurora Cannabis

Cronos Group

Tilray Brands

Zynerba Pharmaceuticals

Cannabis (or marijuana) based medical products have the potential to become the next booming industry.

Epidolex Progresses: Will the Marijuana Drug Market Boom?

GW Pharmaceuticals plc has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GW Pharmaceuticals Enters Oversold Territory

GW stock has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked cannabis stock. 
The post GW Pharmaceuticals Stock Enters Oversold Territory appeared first on InvestorPlace.

GW Pharmaceuticals Stock Enters Oversold Territory

The EU's pharmaceuticals regulator gives Epidyolex the green light for helping treat seizures in children who suffer from two forms of severe epilepsy.

GW Pharmaceuticals Wins Crucial Drug Approval in Europe

Jim Cramer reacts to House Speaker Nancy Pelosi's move to open an impeachment inquiry into President Donald Trump, talks with Disney CEO about his new memoir and interviews GW Pharma CEO.

Everything Jim Cramer on 'Mad Money,' including Trump impeachment, Bob Iger chat, new GW Pharma drug

CARLSBAD, Calif., Sept.  24, 2019  (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that Scott Giacobello, GW’s Chief Financial Officer and Stephen Schultz, GW’s Vice President of Investor Relations will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019 at 4:10 p.m. ET in New York, NY.

GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019

GW Pharmaceuticals (GWPH) wins EU approval for Epidyolex as an adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged two years and above.

GW Pharma Gets EU Nod for Anti-Epileptic Drug Epidyolex

GW Pharmaceuticals stock popped early Monday after the European Medicine Agency approved the biotech company's cannabidiol oil, a medicine called Epidyolex, in two seizure disorders.

News for GW Pharmaceuticals Stock (GWPH)